BBLG · Bone Biologics Corp
$0.56
-0.01 (-2.36%)
At close · Sep 1
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$1.59M
Shares
2.76M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.56
Open$0.56
Day$0.55–0.56
52W close$0.56–2.85
Avg vol 30d590K
Short int157K · 5.7% float · 1.0d
Short vol23%
DataJun 2025–Sep 2026
Filing10-Q · Aug 14
Raw chart and full-history price indicators begin at the captured split on Jun 10, 2025; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 14, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−57%
below
Price vs 50-day avg
−44%
below
RSI (14)
23
oversold
MACD trend
Positive
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−40%
trailing
6-month return
−56%
trailing
YTD return
−61%
this year
Relative strength
−69%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Flat
0% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.68% of float · ▲ +646.3% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
4 holders — near 3-yr low, contrarian setup
Squeeze score
60
elevated · 0–100
Fundamentals
Revenue growth
0%
Y/Y
EPS growth
+91%
Y/Y
Free cash flow
$-2.7M
Quant / Vol
risk profile
Volatility
82%
annualized · 1-yr
Max drawdown
−80%
past year
ATR
11.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−57%
Bearish
Price vs 50-day avg
−44%
Bearish
RSI (14)
23
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Flat
0% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.68% of float · ▲ +646.3% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
4 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1
Now $1 · 0%
Range high $3
vs 200-day avg -57%
vs 50-day avg -44%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BBLG
this stock
Bone Biologics Corp
|
$1.59M | -61.1% | +0.0% | — | 5.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +20.1% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.77B | +3.5% | +20.8% | 19.7 | 2.3% |
|
ARGX
Argenx SE
|
$64.16B | +22.3% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.51B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
Raw-price comparisons begin at the captured split on Jun 10, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BBLG | -6.9% | -40.4% | -56.0% | -2.4% | -61.1% |
| SPY | +0.5% | +1.2% | +13.3% | +2.7% | +12.5% |
| vs SPY | -7.4% | -41.6% | -69.3% | -5.0% | -73.6% |